BioNxt Solutions (XTER:BXT) Net Income: €-5.82 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:BXT BioNxt Solutions Inc XTER:BXT
31 GF Score
Price €0.18
GF Value €0.15
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is BioNxt Solutions Net Income?

BioNxt Solutions XTER:BXT -0.55% 31 Net Income is €-5.82 Mil as of Mar. 2026. GuruFocus rates XTER:BXT with a GF Score™ of 31/100 and a GF Value™ of €0.15 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. BioNxt Solutions's Net Income for the three months ended in Mar. 2026 was €-2.68 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.82 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. BioNxt Solutions's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was €-0.02.


BioNxt Solutions  (XTER:BXT) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

BioNxt Solutions's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


BioNxt Solutions Net Income Related Terms


BioNxt Solutions Net Income Historical Data

* Premium members only.

The historical data trend for BioNxt Solutions's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNxt Solutions Net Income Chart

BioNxt Solutions Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income
Get a 7-Day Free Trial -14.27 -8.60 -5.28 -3.56 -4.35

BioNxt Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.27 -0.83 -0.99 -1.33 -2.68
XTER:BXT
31GF Score
BioNxt Solutions Inc XTER:BXT
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNxt Solutions Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

BioNxt Solutions's Net Income for the fiscal year that ended in Dec. 2025 is calculated as

Net Income(A: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-4.472+0.122+0+0.0010000000000003
=-4.35

BioNxt Solutions's Net Income for the quarter that ended in Mar. 2026 is calculated as

Net Income(Q: Mar. 2026 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.677+0+0+0
=-2.68

Net Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of €-5.82 Mil mean?
BioNxt Solutions (XTER:BXT) has a Net Income of €-5.82 Mil as of Mar. 2026. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on BioNxt Solutions and its competitors.
Is BioNxt Solutions' Net Income too high?
BioNxt Solutions' current Net Income is €-5.82 Mil. Overall, BioNxt Solutions has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' Net Income compare to ZTS?
BioNxt Solutions' Net Income of €-5.82 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Drug Manufacturers company?
A good Net Income depends on the Drug Manufacturers industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on BioNxt Solutions and its competitors. BioNxt Solutions's current Net Income is €-5.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioNxt Solutions (XTER:BXT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €0.18 — trading 20% above its estimated fair value. The current Net Income is €-5.82 Mil. BioNxt Solutions' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For BioNxt Solutions (XTER:BXT), the current Net Income is €-5.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNxt Solutions (XTER:BXT) Overvalued in 2026?

Based on GuruFocus' analysis, BioNxt Solutions stock appears to be overvalued. The current stock price of €0.18 is trading 20% above its estimated GF Value™ of €0.15. GuruFocus considers BioNxt Solutions to be Modestly Overvalued.

Key valuation signals for XTER:BXT:

  • Net Income: €-5.82 Mil
  • GF Value™: €0.15 vs. price of €0.18 (20% above fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the XTER:BXT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioNxt Solutions Business Description

Address 1928 Linden Road, Vancouver, BC, CAN, V6M 1E7
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
31GF Score

Get the complete analysis for XTER:BXT

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.15
GF Value